AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) Discloses Details Regarding A Recent Study


AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) is a company that manufactures biopharmaceutical products that help treat acute medical conditions. Currently, it seeks to further develop tivozanib which is its most recent candidate. The company in conjunction with EUSA Pharma unveiled results from TiNivo study.

Current state of affairs

These companies admit that this Phase 2 study pulled along with several challenges. However, they are glad it inspires hope that they will succeed at handling metastatic renal cell carcinoma. AVEO terms oral (PO) tivozanib a critical element in the study. It seeks to see the way it acts when combined with intravenous (IV) nivolumab.

The business guru unveiled the results at the European Society of Medical Oncology congress. The responsible management conducts this congress on a yearly basis. Researchers conducted the study among about 28 patients. According to them, the number was ideal for the Phase 1b/2 study.

Researchers sought to find out important aspects such as anti-tumor activity, tolerability and above all the safety of the dose. They admit that the combination was ideal. The associated tolerability even exceeded their set expectations. They say that hypertension was one of the extreme events associated with the treatment and that it affected about 60% of patients.

Genitourinary Oncology Committee’s ex-Chairman Doctor Bernard Escudier opined, “The ability to give a VEGF inhibitor and immuno-oncology agent both at full dose and strength could serve to deliver both improved outcomes and an improved patient experience.”

A closer outlook

The official expects that soon he will be in a position to better understand the full potential of tivozanib. Escudier counts on the randomized study that is currently underway since he believes it will reveal more regarding the immunotherapy.

The President of AVEO Michael Bailey has spoken in relation to the various cancers. According to the leader, the IO-TKI combinations have proven effective which a stride towards the right direction.

Bailey asserts that as a company they will keep focusing on expanding their clinical strategies. The leader believes in tivozanib and its remarkable effects on metastatic RCC and promises they will soon be doing much more.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.